An interventional study of Tapentadol and Placebo in Breast Cancer, sponsored by Shaukat Khanum Memorial Cancer Hospital & Research Centre. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Shaukat Khanum Memorial Cancer Hospital & Research Centre · Not applicable, Interventional, and Prevention
This study evaluated the preemptive analgesic efficacy of Tapentadol in reducing peri operative analgesic requirements among patients undergoing breast cancer surgery.
A double blinded prospective RCT was conducted with 70 patients undergoing breast cancer surgery with 35 patients being studied with Administrated drug \& other 35 as placebo. Intraoperative \& postoperative morphine consumption was calculated and documented.
12,543 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 70 is close to the median of 72 across 9,302 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Shaukat Khanum Memorial Cancer Hospital & Research Centre is the lead sponsor of 23 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Control drug (Tapentadol )
Drug: Tapentadol
Placebo sodium bicarbonate/ peppermint oil tablet
Other: Placebo
75 mg oral tapentadol given 1 hour before surgery in control group and placebo tablet was given in Group B. Intraoperative and post operative morphine consumption and pain scores at 1,2,3,4 hours were calculated.
Placebo tablet was given in group B.
Intraoperative and postoperative morphine consumption
During the course of surgery and up to 4 hours surgery Intraoperative and postoperative morphine consumption.
Time frame: During the course of surgery and up to 4 hours surgery
Plan to share: No — No plan to share IPD. Due to confidentiality of patients data.
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shaukat Khanum Memorial Cancer Hospital & Research Centre